Study at UCC |
Current Students |
Research |
Staff |
Teaching & Learning |
Visitors |
Alumni |
About UCC
JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Roehr, Charles Christoph C. | |
| dc.contributor.author | Banerjee, Rupjani | |
| dc.contributor.author | Alarcon-Allen, Ana | |
| dc.contributor.author | Dempsey, Eugene M. | |
| dc.date.accessioned | 2019-05-29T11:28:49Z | |
| dc.date.available | 2019-05-29T11:28:49Z | |
| dc.date.issued | 2019-02-25 | |
| dc.identifier.citation | Roehr, C. C. C., Banerjee, R., Alarcon-Allen, A. and Dempsey, E. (2019) 'Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes', Cochrane Database of Systematic Reviews, Issue 2, CD013275 (9pp). doi: 10.1002/14651858.CD013275 | en |
| dc.identifier.issued | 2 | en |
| dc.identifier.startpage | 1 | en |
| dc.identifier.endpage | 9 | en |
| dc.identifier.issn | 1465-1858 | |
| dc.identifier.uri | http://hdl.handle.net/10468/7998 | |
| dc.identifier.doi | 10.1002/14651858.CD013275 | en |
| dc.description.abstract | This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes. | en |
| dc.description.sponsorship | National Institute for Health Research (Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth) | en |
| dc.format.mimetype | application/pdf | en |
| dc.language.iso | en | en |
| dc.publisher | John Wiley & Sons, Ltd. on behalf of the Cochrane Collaboration | en |
| dc.relation.uri | https://doi.org//10.1002/14651858.CD013275 | |
| dc.rights | © 2019, the Cochrane Collaboration. Published by John Wiley & Sons, Ltd. All rights reserved. | en |
| dc.subject | Methylxanthine | en |
| dc.subject | Caffeine | en |
| dc.subject | Cardiorespiratory adaptation | en |
| dc.subject | Neurodevelopmental outcomes | en |
| dc.title | Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes | en |
| dc.type | Other | en |
| dc.internal.authorcontactother | Eugene Dempsey, Paediatrics & Child Health, University College Cork, Cork, Ireland. +353-21-490-3000 Email: g.dempsey@ucc.ie | en |
| dc.internal.availability | Full text available | en |
| dc.check.info | Access to this article is restricted until 12 months after publication by request of the publisher. | en |
| dc.check.date | 2020-02-25 | |
| dc.date.updated | 2019-05-29T11:15:03Z | |
| dc.description.version | Published Version | en |
| dc.internal.rssid | 487025689 | |
| dc.contributor.funder | National Institute for Health Research
|
en |
| dc.description.status | Peer reviewed | en |
| dc.identifier.journaltitle | Cochrane Database of Systematic Reviews | en |
| dc.internal.copyrightchecked | Yes | |
| dc.internal.licenseacceptance | Yes | en |
| dc.internal.IRISemailaddress | g.dempsey@ucc.ie | en |
| dc.identifier.articleid | CD013275 | en |
| dc.identifier.eissn | 1469-493X |
